Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports  

作　　者：Masaki Okajima Yoshinori Takahashi Takaaki Kaji Naohiko Ogawa Hideyuki Mouri 

机构地区：[1]Intensive Care Unit,Kanazawa University Hospital,Kanazawa 920-8641,Ishikawa,Japan [2]Department of Rheumatology,Kanazawa University Hospital,Kanazawa 920-8641,Ishikawa,Japan [3]Department of Nephrology,Kanazawa University Hospital,Kanazawa 920-8641,Ishikawa,Japan [4]Department of Respiratory Medicine,Kanazawa University Hospital,Kanazawa 920-8641,Ishikawa,Japan

出　　处：《World Journal of Clinical Cases》2020年第21期5320-5325,共6页世界临床病例杂志

摘　　要：BACKGROUND Nafamostat mesylate(NM)may prove to be one of the key drugs effective against coronavirus disease 2019(COVID-19)because of its anti-viral properties and the potential to manage coagulopathy.However,NM tends to increase serum potassium levels.CASE SUMMARY We observed hyperkalemia immediately after NM administration(200 mg/d)in four consecutive patients who were admitted to the Kanazawa University Hospital with severe COVID-19 pneumonia.Urinary potassium excretion decreased after NM administration in three patients who underwent urinalysis.CONCLUSION NM is likely to produce hyperkalemia in patients with COVID-19.Therefore,it is necessary to monitor serum potassium values closely after NM initiation in COVID-19 patients who need respiratory support.

关 键 词：COVID-19 Nafamostat HYPERKALEMIA Disseminated intravascular coagulation Respiratory insufficiency Case report 

分 类 号：R563.1[医药卫生—呼吸系统] R589.4[医药卫生—内科学]